XNAS · Biotechnology
Last stored close · Sep 18, 2026
Close · Sep 18, 2026
$494.63-0.53%
Model Target
available with Pro
Implied upside
vs the model target
Valuation methods
the methods behind the target
TickerWhale Score
56/100
Positive
Score components
TickerWhale View
United Therapeutics scores 56 out of 100 overall, which we rate positive. Risk is its strongest area and Technical its weakest.
What helps
- Quality & growth
- Valuation
- Risk
What to watch
- Technical
Quality & growth
30%59Positive
- Revenue growth 2.5%
- EPS growth 8.9%
Valuation
25%68Positive
- P/E 17.3
- EV/Sales 6.6
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
#422 by market cap in our coverage · ~1,400 employees · Listed 1999-06-17 · www.unither.com
Price history
Intraday to five-year windows are free with an account
Members switch between 1D, 1M, 6M, 1Y, 2Y and 5Y and see the live price. Signed out, this is the one-year stored series the technicals below are computed from.
Market intelligence
Peer position
#70 / 139sector rank by TickerWhale Score
TickerWhale Score 56 vs sector average 55.1 (+0.9)
Revenue growth (industry)Top 76%
Gross margin (industry)Top 53%
Return on equity (industry)Top 14%
P/E (industry)Cheaper than 89%
Technical analysis
our read · what classic indicators sayTickerWhale technical read
38/100Weak vs universe
Ranks 38th of 100 covered names on our technical composite — the composite itself scores 41/100 · 25% of the TickerWhale Score
Classic chart indicators
Neutral
2 buy · 2 sell · 4 neutral of 8 votes
TickerWhale rates UTHR's technical setup weak — 38th percentile of the covered universe. Classic chart indicators lean neutral — they read this stock on its own over days, where our score ranks it against every covered name over months, so the two often part company.
Moving averages
0 / 9constructive
- vs 200-day-5.7%
- vs 50-day-4.3%
Momentum
Mixed
- RSI (14)41 · neutral
- Stochasticbuy
- CCIneutral
- Williams %Rneutral
Trend
Mixed
- ADX (14) trend strength17· weak trend
- MACD (12,26,9)buy(histogram 0.101)
How the classic verdict is reached
Moving averages (9) agree on sell — 0 buy vs 9 sell — and carry one vote between them.
Oscillators (7) vote individually: 2 buy · 1 sell · 4 neutral.
Result — 2 buy vs 2 sell of 8 votes = Neutral. Neutral votes never decide the verdict.
Fundamentals & valuation
2026-09-18 · revised_latestValuation multiples
- P/E (TTM)17.3
- P/S (TTM)7.2
- P/B3.5
- EV/EBITDA—
- EV/Sales6.6
- PEG1.94
Profitability & returns
- Gross margin86.1%
- Net margin41.6%
- ROE21.3%
- Debt/Equity0.00
Growth
- Revenue growth (YoY)2.5%
- EPS growth (YoY)8.9%
Green favourable · red stretched — multiples and D/E vs industry peers, margins and growth vs absolute thresholds.
Market capitalisation — $22.7B
Fundamentals history
Reported statement totals across recent periods.
Fundamentals are stored revised/latest (ADR-009): each period reflects the most recent vendor refresh, NOT point-in-time as-reported values. Do not use this series to claim what was known on a past date.
Model Target
Model Target is a Pro feature
Scores, factors and technicals stay free. The model's price target is part of TickerWhale Pro.
The Model Target is a TickerWhale Pro feature
A target exists for this name — the model priced it in the latest nightly run. Pro members see the target, its range and the methods behind it; one name's target is free every trading day.
Or see the current free one: MU →
Peers
| Company | Score | Pulse | P/E | P/E fwd | P/B | EV/Sales | Price | Chg | Estimate | Upside | Rev. gr. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| UTHRCurrentUnited Therapeutics | 56 | 41 | 17.3 | — | 3.5 | 6.6 | $494.63 | -0.53% | +2.5% | ||
| EXELExelixis | 81 | 80 | 17.6 | — | 8.2 | 6.1 | $58.36 | -0.22% | +9.2% | ||
| INCYIncyte | 81 | 76 | 16.2 | — | 4.1 | 3.8 | $125.31 | -1.81% | +26.9% | ||
| ACADAcadia Pharmaceuticals | 80 | 63 | 12.4 | — | 3.6 | 3.8 | $27.29 | -0.58% | +11.8% | ||
| OSCROscar Health Inc - | 78 | 67 | 19.5 | — | 5.2 | 0.5 | $32.13 | +0.47% | +43.1% | ||
| TGTXTG Therapeutics | 77 | 73 | 20.3 | — | 14.8 | 11.5 | $56.87 | +0.71% | +76.1% |
News, sentiment, the Street view and Ask Willy are free with an account
A free account shows the stories attached to this name, the Sentiment Signal breakdown, analyst consensus, the options read and the AI narration of the model output.